Sharemaestro company-news research for GSK plc (GSK), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
BUE
Argentina
Provisional evidence
Company news sentiment
Latest GSK news and sentiment
GSK plc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
10 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone72/100
→
Published 30-day score50/100
Latest source headline
GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?
finance.yahoo.com · 24 Sep 2026 22:41
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
10 current stories are mapped specifically to GSK.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.014.
Confidence is 14/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
14/100
Confidencethin evidence
78%/100
Company news10 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
31 Aug15 Sep29 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.014 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness28
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks14 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202650ARS 19930.0-0.3%
18 Sep 202651ARS 20000.0+4.2%
11 Sep 202652ARS 19200.0-2.8%
04 Sep 202653ARS 19760.0-2.9%
28 Aug 202650ARS 20350.0-2.7%
21 Aug 202651ARS 20910.0+7.0%
14 Aug 202652ARS 19540.0-6.1%
07 Aug 202653ARS 20800.659631+2.6%
Provisional evidence
News subjects
What is shaping the score
Market update505 stories · 50%
Deals and strategy503 stories · 30%
Regulatory and legal721 stories · 10%
Earnings501 stories · 10%
Source mix
Where the evidence comes from
finance.yahoo.com5210 stories · 100%
Recurring subjects
Subjects appearing most often
Oncology6Pharma5Clinical Trials5M A3Future Cash Flows3Fda Approval3Earnings3Share Price2Pharmaceuticals2Free Cash Flow2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral27 Sep 14:00
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 27 Sep 14:00 | 50 | +0 | 13/100 (-1) | 10 (0) | Provisional |
| 24 Sep 23:59 | 50 | -1 | 14/100 (-2) | 10 (+1) | Provisional |
| 17 Sep 23:59 | 51 | +0 | 16/100 (-1) | 9 (+2) | Provisional |
| 14 Sep 23:59 | 51 | -2 | 17/100 (-10) | 7 (-5) | Provisional |
| 03 Sep 23:59 | 53 | +0 | 27/100 (-2) | 12 (0) | Provisional |
| 02 Sep 23:59 | 53 | +2 | 29/100 (+3) | 12 (+2) | Provisional |
| 01 Sep 23:59 | 51 | +1 | 26/100 (+11) | 10 (-8) | Provisional |
| 24 Aug 23:59 | 50 | -2 | 15/100 (-3) | 18 (-9) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 10 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Regulatory and legal1 story
0.0%100.0%
Market update1 story
0.0%0.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Deals and strategyNot used in direction
GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?
GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 mill…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million. GSK (NYSE:GSK) plans to develop the experimental drug for multiple myeloma, adding another potential treatment to its blood-cancer portfolio. READ ALSO: Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? For investors, the deal is another piece of GSK's broader push into onc
- Published
- 24 Sep 2026 22:41
- News subject
- Deals and strategy
- Why this score
- Business expansion
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
M AMultiple MyelomaOncologyT Cell Engagers
—Unscored
Market updateNot used in direction
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potenti…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights outside Greater China. HUTCHMED will run the global Phase I clinical trials beginning in H2 2026, after which GSK assumes all operational and commercialization responsibilities across ex-China marke
- Published
- 24 Sep 2026 20:59
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetClinical TrialsFree Cash FlowM AOncologyPharma
—Unscored
EarningsNot used in direction
GSK (LSE:GSK) Stock Looks Reasonable As Its 58% Run Continues
GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately supported by the earnings power of the business? Over the…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately supported by the earnings power of the business? Over the past 5 years GSK shares have returned 58.4%, which puts real weight on whether the current earnings justify where the stock now trades. Recent deals in cancer therapies, including new T cell engager and antibody conjugate programs, may support expectations for future profit streams and affect how much investo
- Published
- 17 Sep 2026 08:11
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFree Cash FlowInvestmentsOncologyPharmaceuticalsShare Price
—Unscored
Deals and strategyNot used in direction
GSK (LSE:GSK) Agrees Multiple Myeloma T Cell Deal
GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell therapy targeting multiple myeloma. GSK plans to …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell therapy targeting multiple myeloma. GSK plans to close its German vaccine manufacturing site and consolidate production in Canada, with associated job reductions and supply chain changes. The acquisition of Chimagen's trispecific T cell-engager and the German vaccine site shutdown sit alongside other important parts of GSK's story. Our analysis turns up 4 ot
- Published
- 17 Sep 2026 01:12
- News subject
- Deals and strategy
- Why this score
- Business expansion
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
AcquisitionOncologyPharmaceuticalsVaccine Manufacturing
—Unscored
Deals and strategyNot used in direction
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro (zidesamtinib), for the first-line treatment of patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Jideytro is a next-generation,…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro (zidesamtinib), for the first-line treatment of patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Jideytro is a next-generation, highly selective ROS1 inhibitor that is already approved for previously treated ROS1-positive NSCLC. The drug was added to GSK's oncology portfolio as a late-stage candidate through the recent acquisition ofNuvalent. Year to date, GSK's shares have lost 1.9% against the industry's 5.2% growth.Zacks Investment
- Published
- 14 Sep 2026 15:14
- News subject
- Deals and strategy
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechClinical TrialsEarnings Per ShareFda ApprovalOncology
—Unscored
Market updateNot used in direction
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
HUTCHMED (China) Limited — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ("ATTC"), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
HUTCHMED (China) Limited — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ("ATTC"), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English — HONG KONG and FLORHAM PARK, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK
- Published
- 03 Sep 2026 04:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsDrug DevelopmentM AOncology
—Unscored
Market updateNot used in direction
GSK (LSE:GSK) Stock Looks Reasonable On Its 54% Five Year Run
GSK stock has delivered a strong 54.4% total return over the past five years, yet current valuation checks still suggest the shares lean cheap rather than fully priced in. That mix of solid long term gains and a high value score raises the question of whether the market is still underesti…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
GSK stock has delivered a strong 54.4% total return over the past five years, yet current valuation checks still suggest the shares lean cheap rather than fully priced in. That mix of solid long term gains and a high value score raises the question of whether the market is still underestimating the company. Over the past 5 years, GSK has returned 54.4%, which points to meaningful value creation for longer term holders despite some recent short term share price softness. The planned Phase 3 trial of GSK's next generation mRNA flu vaccine can support confidence in the company's pipeline. However
- Published
- 02 Sep 2026 08:10
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFuture Cash FlowsPharmaShare PriceSplitUndervalued
72/100 tone
Regulatory and legal
GSK (LSE:GSK) Wins First Global Approval For Chronic Hepatitis B Functional Cure
GSK (LSE:GSK) has received the world's first regulatory approval for Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B virus infection in Japan. The Japanese approval follows Phase III trial data that showed significant functional cure rates in patients with chronic hepa…
100% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
GSK (LSE:GSK) has received the world's first regulatory approval for Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B virus infection in Japan. The Japanese approval follows Phase III trial data that showed significant functional cure rates in patients with chronic hepatitis B. The decision represents an important development for GSK's pipeline and may influence the standard of care for chronic hepatitis B treatment globally. For readers tracking how advances like GSK's Hibsago might influence related opportunities, it is worth looking at a wider group of healthcare AI focus
- Published
- 02 Sep 2026 03:07
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won, Regulatory Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 100% of directional evidence · 26.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetFda ApprovalFuture Cash FlowsHealthcareInfectious DiseasesPharma
—Unscored
Market updateNot used in direction
GSK (LSE:GSK), What Is Behind The Latest Attention?
GSK (LSE:GSK) is back in focus after presenting positive phase II data for its mRNA seasonal flu vaccine and confirming plans to start a phase III trial in September 2026, following Fast Track designation in the US. Against this backdrop of pipeline news, GSK's share price has shown mixed…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
GSK (LSE:GSK) is back in focus after presenting positive phase II data for its mRNA seasonal flu vaccine and confirming plans to start a phase III trial in September 2026, following Fast Track designation in the US. Against this backdrop of pipeline news, GSK's share price has shown mixed short term momentum, with a 1-day share price return of 0.97% but a 30-day share price return that is down 3.11%, while the 1-year total shareholder return of 34.36% points to much stronger longer term performance as the market reassesses both growth prospects and risk around its portfolio. Extend your resear
- Published
- 02 Sep 2026 02:12
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Clinical TrialsEarningsFuture Cash FlowsPatentsPharmaRevenue Growth
57/100 tone
GSK plc(NYSE:GSK) plans to launch a Phase 3 clinical trial in September for its experimental mRNA seasonal influenza vaccine after achieving superior immune responses in mid-stage testing compared to currently licensed vaccines. Strong Mid-Stage Results Data presented at the OPTIONS XIII …
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
GSK plc(NYSE:GSK) plans to launch a Phase 3 clinical trial in September for its experimental mRNA seasonal influenza vaccine after achieving superior immune responses in mid-stage testing compared to currently licensed vaccines. Strong Mid-Stage Results Data presented at the OPTIONS XIII Conference for the Control of Influenza revealed that the company's vaccine candidate generated higher immune responses against every tested strain than standard and high-dose inactivated vaccines in both younger and older adults. The trial, known as Flu-028, evaluated safety and immunogenicity in 971 adults a
- Published
- 01 Sep 2026 12:29
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- <0.1% of directional evidence · 27.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Clinical TrialsFda ApprovalPharmaVaccines
Earlier company news
GSK news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 38 older GSK headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to GSK, but the headline and available text are not mainly about GSK plc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of GSK sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.